Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) EBT (2022 - 2025)

Historic EBT for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $37.0 million.

  • Indivior Pharmaceuticals' EBT rose 2333.33% to $37.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $196.0 million, marking a year-over-year increase of 35581.4%. This contributed to the annual value of $20.0 million for FY2024, which is 11379.31% up from last year.
  • Latest data reveals that Indivior Pharmaceuticals reported EBT of $37.0 million as of Q3 2025, which was up 2333.33% from $62.0 million recorded in Q2 2025.
  • Indivior Pharmaceuticals' EBT's 5-year high stood at $73.0 million during Q1 2024, with a 5-year trough of -$256.0 million in Q4 2022.
  • Moreover, its 4-year median value for EBT was $56.0 million (2022), whereas its average is $2.4 million.
  • Its EBT has fluctuated over the past 5 years, first plummeted by 43518.52% in 2023, then surged by 15123.97% in 2025.
  • Over the past 4 years, Indivior Pharmaceuticals' EBT (Quarter) stood at -$256.0 million in 2022, then skyrocketed by 123.83% to $61.0 million in 2023, then tumbled by 37.7% to $38.0 million in 2024, then fell by 2.63% to $37.0 million in 2025.
  • Its last three reported values are $37.0 million in Q3 2025, $62.0 million for Q2 2025, and $59.0 million during Q1 2025.